BOSTON SCIENTIFIC TO ADD CARDIAC ABLATION SYSTEM WITH $150 MIL. STOCK OFFER FOR EP TECHNOLOGIES; CAN SHOPPING SPREE CONTINUE? 6 DEALS IN 14 MONTHS
This article was originally published in The Gray Sheet
Boston Scientific's $150 mil. proposed merger with EP Technologies would add one of the two radiofrequency catheter systems with FDA approval for therapeutic ablation to Boston Scientific's rapidly expanding portfolio of minimally invasive devices. On Oct. 9, the firms announced a definitive agreement with an expected closing during the first quarter of 1996.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.